Avita Medical announces clinical study results of RECELL
AVITA Medical announced results from a clinical study highlighting the potential benefits of the RECELL Autologous Cell Harvesting Device in the treatment of deep partial-thickness facial burns. The results showed excellent cosmetic outcomes when RECELL was used on deep partial-thickness facial burns, an injury for which treatment with standard of care often results in dyspigmentation and hypertrophic scarring at the seams of skin grafts. The results were presented by Nicholas Walker, MD, Wake Forest University School of Medicine, North Carolina, at the American Burn Association 50th Annual Meeting in Chicago. RECELL is an investigational medical device in the U.S. that is designed to enable medical professionals to produce, at the point-of-care, a REGENERATIVE EPIDERMAL SUSPENSION using a small sample of the patient's own skin. The autologous suspension contains cells necessary to regenerate epidermis and provides a new way to achieve permanent closure in burns and other wounds while reducing the amount of skin harvested at the time of surgery. Reduction in donor-site skin requirements has important benefits from both clinical and health economic perspectives.